Is Danaher Corporation (DHR) A Good Stock To Buy Now?

Is DHR a good stock to buy? We came across a bullish thesis on Danaher Corporation on Buffett_N_Me’s Substack. In this article, we will summarize the bulls’ thesis on DHR. Danaher Corporation's share was trading at $190.11 as of March 19th. DHR’s trailing and forward P/E were 37.80 and 22.52 respectively according to Yahoo Finance.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. Danaher has recently drawn investor attention following a notable pullback of over 30% from its 52-week highs, presenting what appears to be an attractive entry point into one of the highest-quality compounders in the healthcare and life sciences sector. The company, widely recognized for its Danaher Business System, has consistently demonstrated operational excellence, disciplined capital allocation, and a strong track record of value-accretive acquisitions.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
While near-term headwinds have emerged due to a slowdown in biotech funding—particularly among smaller labs and research-driven customers—this pressure is widely viewed as cyclical rather than structural. With approximately $24 billion in revenue, operating margins near 18%, and net margins around 14%, Danaher maintains strong profitability alongside a healthy balance sheet, evidenced by a modest debt-to-equity ratio of ~0.35 and a current ratio of ~1.8. Despite trading at a forward price to earnings ratio of ~24 and EV/EBITDA of ~20, the company’s premium valuation reflects its consistent ability to compound earnings and free cash flow over time.
Importantly, Danaher remains deeply embedded in long-term secular growth trends, including biologics manufacturing, diagnostics, and life sciences research, all of which are expected to expand meaningfully over the coming years. As biotech funding cycles normalize, demand recovery is likely to follow, positioning the company for renewed growth. In this context, the recent decline offers a compelling opportunity to accumulate shares of a proven long-term compounder at a relative discount, with favorable risk-reward skew and strong upside potential.
Previously, we covered a bullish thesis on Danaher Corporation by Best Anchor Stocks in May 2025, which highlighted resilient earnings, bioprocessing recovery, conservative guidance, and disciplined buybacks. Danaher’s stock price has depreciated by approximately 3.35% since our coverage. Buffett_N_Me shares a similar view but emphasizes the recent pullback, biotech funding slowdown, and long-term compounding opportunity.